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Objective: Impaired amyloid clearance has been proposed to contribute to β-amyloid deposition in sporadic
late-onset Alzheimer's disease (AD). Low density lipoprotein receptor-related protein 1 (LRP-1) is involved in
the active outward transport of β-amyloid across the blood–brain barrier (BBB). The C667T polymorphism
(rs1799986) of the LRP-1 gene has been inconsistently associated with AD in genetic studies.
We aimed to elucidate the association of this polymorphismwith in-vivo brain amyloid load of AD patients using
amyloid PET with [11C]PiB.
Materials and methods: 72 patients with very mild to moderate ADwere examined with amyloid PET and C667T
polymorphismwas obtained using TaqMan PCR assays. The association of C667T polymorphismwith global and
regional amyloid load was calculated using linear regression and voxel based analysis, respectively. The effect of
the previously identiﬁed modulator of amyloid uptake, the apolipoprotein E genotype, on this association was
also determined.
Results: The regression analysis between amyloid load and C667T polymorphism was statistically signiﬁcant
(p = 0.046, β= 0.236). In an additional analysis ApoE genotype and gender were identiﬁed to explain further
variability of amyloid load. Voxel based analysis revealed a signiﬁcant (p b 0.05) association between C667T
polymorphism and amyloid uptake in the temporo-parietal cortex bilaterally. ApoE did not interact signiﬁcantly
with the LRP-1 polymorphism.
Discussion: In conclusion, C667T polymorphism of LRP-1 is moderately but signiﬁcantly associated with global
and regional amyloid deposition in AD. The relationship appears to be independent of the ApoE genotype. This
ﬁnding is compatible with the hypothesis that impaired amyloid clearance contributes to amyloid deposition
in late-onset sporadic AD.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The characteristic histopathological features of Alzheimer's disease
(AD) include senile plaques and neuroﬁbrillary tangles in conjunction
with loss of neurons and synapses (Braak and Braak, 1991; Thal et al.,
2002). The major constituent of senile plaques is amyloid beta peptideand Psychotherapy, Klinikum
r. 26, 81675 Munich, Germany.
c. This is an open access article unde(Aβ). The amount and progression of amyloid deposition during the
course of AD can be monitored using positron emission tomography
(PET) by means of the radiotracer [11C]PiB (Pittsburgh compound B)
(Grimmer et al., 2010; Villemagne et al., 2011). It is known that the ε4 al-
lele of the apolipoprotein E (APOE) gene modulates amyloid increase
gene-dose dependently (Grimmer et al., 2010). Mutations leading to an
overproduction of amyloid are recognized as amajor cause of aggregation
of the peptide in early onset familial AD (Hardy and Selkoe, 2002). How-
ever, the reasons for β-amyloid deposition in late onset sporadic AD are
less clear (Duyckaerts et al., 2009). One hypothesis is that an impaired
clearance of β-amyloid contributes to cerebral amyloid deposition (Thal,
2009). This notion is supported by the ﬁnding that AD patients show
identical β-amyloid production rates but decreased β-amyloid clearance
rates relative to cognitive healthy controls (Mawuenyega et al., 2010).r the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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contained in the interstitial ﬂuid (ISF) are cleared from the brain
via different pathways including internalization by neurons or the
endovascular unit (Kandimalla et al., 2009), transport across the blood–
brain-barrier (BBB) (Shibata et al., 2000) and extracellular degradation
by proteases including NEP (Iwata et al., 2000) or IDE (Miners et al.,
2008). While ISF of white matter seems to be preferentially drained into
the cerebrospinal ﬂuid (CSF) directly, the interstitial ﬂuid of gray matter
appears to ﬂow outward via perivascular spaces which are located along-
side cerebral arteries and empty into cervical lymph nodes (Carare et al.,
2008; Szentistvanyi et al., 1984; Weller et al., 1998; Zhang et al., 1992).
The latter drainage pathway could be impaired in late-onset AD. As a con-
sequence, amyloid may be less efﬁciently cleared from the brain and be-
come deposited in the form of β-amyloid plaques (Grimmer et al., 2012).
Low density lipoprotein receptor-related protein 1 (LRP-1) is a 600
kDa type-I transmembrane glycoprotein, the largest of the low density
lipoprotein receptor family (Herz and Strickland, 2001; Van Leuven
et al., 1994). It has multiple functions: transportation of cholesterol,
recognition of at least 30 structurally diverse ligands, transcytosis of
ligands across the BBB, and transmembrane and nuclear signaling
(Herz and Strickland, 2001; Jaeger and Pietrzik, 2008). It provides a
homeostatic control mechanism of amyloid clearance including
cell-surface LRP-1 at the BBB and cerebrovascular cell mediating
brain-to-blood amyloid clearance (Jaeger and Pietrzik, 2008). Circulat-
ing soluble LRP-1 acts as a peripheral “sink” for plasma amyloid
preventing access of free amyloid to the brain, and LRP-1 in the liver
mediates systemic amyloid clearance (Deane et al., 2009; Pﬂanzner
et al., 2011; Yamada et al., 2008; Zlokovic et al., 2010).
LRP-1 may play an important role in AD, since in mice inhibition of
LRP-1 by the inhibitor RAP (receptor associated protein) or by LRP-1 an-
tibodies leads to substantial reduction in amyloid clearance (Shibata
et al., 2000; Williams et al., 1992).
The C667T polymorphism in exon 3 (rs1799986) of the LRP-1 gene
on chromosome 12q13–q14, which does not alter the amino acid
sequence (Kang et al., 1997), has been inconsistently associated with
AD (Beffert et al., 1999; Deng et al., 2006; Forero et al., 2006; Glaser
et al., 2004; Hatanaka et al., 2000; Kamboh et al., 1998; Kang et al.,
1997, 2000; Kolsch et al., 2003; Pritchard et al., 2005).
Physiologically Aβ is processed in the cell and not deposited in the
PVS (perivascular spaces — the space between glia limitans and
adventitial pericytes). In AD Aβ/ApoE deposits are found in the PVS
and near the basement membrane (Thal, 2009) predominantly around
small arteries (Weller et al., 1998) suggesting impaired perivascular
drainage. LRP-1 is involved in the amyloid clearance system from the
brain into circulation (Deane and Zlokovic, 2007). LRP-1 binds to
ApoE-linked Aβ as well as to Aβ alone (Fuentealba et al., 2010; Jaeger
and Pietrzik, 2008) and mediates endocytosis of the LRP-1/ApoE/Aβ-
complex or LRP-1/Aβ-complex (Deane et al., 2008; Gylys et al., 2003).
An association study found a protective effect of the TT LRP-1 polymor-
phism against AD only in ApoE ε4 carriers (Kamboh et al., 1998).
Since LRP-1 is involved in multiple mechanisms which could have
an inﬂuence on the pathogenesis of AD and additionally impact Aβ
transcytosis, internalization, processing and degradation, we wished
to elucidate on how the C667T polymorphism of the LRP-1 gene is
associated with cerebral amyloid load in a cohort of 72 AD patients.
Because LRP-1 is associated with ApoE ε4 we also examined the associ-
ation of LRP-1 and ApoE genotype on amyloid load.
2. Materials and methods
2.1. Ethics statement
The study protocol was submitted to the ethics committee of the
Faculty of Medicine of the Technische Universität München, which
raised no objections, and was approved by radiation protection author-
ities. All patients gave written informed consent and all clinicalinvestigations have been conducted in accordance with the principles
of the Declaration of Helsinki, sixth revision.
2.2. Patient recruitment, inclusion and exclusion criteria
Recruitment and inclusion criteria of the patient sample have been
described elsewhere (Grimmer et al., 2010). Brieﬂy, outpatients with
very mild to moderate dementia, as rated on the Clinical Dementia
Rating scale (CDR; global CDR score of 0.5–2) (Morris et al., 1989)
were included. Only patients who fulﬁlled the National Institute of Neu-
rological and Communicative Disorders and Stroke and the Alzheimer's
Disease andRelatedDisorders Association (NINCDS–ADRDA) diagnostic
criteria for Probable Alzheimer's Diseasewere involved (McKhann et al.,
1984). To enhance the likelihood of underlying AD pathology cranial
positron emission tomography with 2-deoxy-2-[18F]Fluoro-D-glucose
([18F]FDG-PET) ﬁndings typical for AD were also required for inclusion
(Hoffman et al., 2000; Jagust et al., 2007), i.e. hypometabolism in the
temporo-parietal and posterior cingulate cortex with relative sparing
of the primary sensorimotor cortex on visual inspection (Minoshima
et al., 1995). Thus, they also met the new National Institutes on Aging
and the Alzheimer's Association (NIA–AA) diagnostic criteria for proba-
ble AD dementia with evidence of the AD pathophysiological process
(McKhann et al., 2011). The study's participants had been referred
for the evaluation of cognitive impairment by general practitioners,
neurologists, psychiatrists, or other institutions, and had undergone a
standardized diagnostic procedure including the Mini-Mental State
Examination (MMSE) (Folstein et al., 1975) and ApoE genotyping
(Zivelin et al., 1997).
All patients underwent cranial magnetic resonance imaging (MRI)
on a 1.5 T scanner to assess structural brain abnormalities. In addition,
[11C]PiB-PET was used to assess brain amyloid burden.
2.3. Brain imaging
Structural MRI, [18F]FDG-PET, and [11C]PiB-PET of the brain were
obtained using standard procedures (Grimmer et al., 2009a,b, 2010).
The [11C]PiB images were co-registered to high resolution MRI scans
and normalized to the MNI space using the warping parameters of the
MRI to obtain inter-individually comparable images. Using the standard
reference tissue model (Ziolko et al., 2006) a relative measure of global
cerebral [11C]PiB uptakewas obtained by calculating a cerebral cortex to
cerebellar vermis (C/cv) ratio of each patient's [11C]PiB SUV 40–70 min
scan to control for between-subject differences in tracer uptake using
standard methods (Grimmer et al., 2009a,b, 2010; Ziolko et al., 2006).
2.4. CAA
To reduce the likelihood of a co-existent cerebral amyloid
angiopathy (CAA) only the patients that did not show lacunes on
ﬂuid-attenuated inverse recovery (FLAIR) MRI-images or microbleeds
on T2* images were included (Goos et al., 2010).
2.5. LRP-1 C667T polymorphism genotyping
The genotypes were determined using TaqMan® polymerase chain
reaction (PCR) assays (single nucleotide polymorphism (SNP) assays-
on-demand) on a StepOne analyzer with StepOne software v2.1 (all as-
says, machine, and software were from Applied Biosystems, Carlsbad,
CA, USA) according to establishedmethods (Guo et al., 2012). Genotyp-
ingwas performed in 96well-plates; theﬁnal reaction volumewas 20 μl
using 20 ng of genomic DNA, 10 μl of TaqMan® master mix and 1 μl of
20× SNP genotyping assay mix. PCR plates were read after heating at
95 °C for 10 min, followed by forty cycles of denaturation at 95 °C for
15 s and annealing/extension at 60 °C for 1 min. Duplicate genotypes
were determined for 12.5% of the samples (9 of 72) for quality control
reasons.
Table 1
Characteristics of the patient sample.
Demographic and clinical data
Number 72
Male:Female 42:30
LRP-1 C667T genotype CC:CT:TT 57:14:1
ApoE ε 4 alleles: 0:1:2 29/28/15
Age at PET: mean ± SD (range) 69.2 ± 7.86 (50–84)
MMSE: mean ± SD (range) 24.7 ± 3.77 (11–30)
CDR SOB: mean ± SD (range) 3.34 ± 2.126 (0.5–10.0)
[11C]PiB uptake ratios (C/cv): mean ± SD (range) 1.77 ± 0.347 (1.0–2.4)
ApoE ε4: apolipoprotein E epsilon 4; CDR-SOB: clinical dementia rating sum of boxes;
C/cv: cerebral to cerebellar vermis; LRP-1: low density lipoprotein receptor-related
protein 1; MMSE: Mini-Mental State Examination; PiB: Pittsburgh compound B; ROI: re-
gion of interest; and SD: standard deviation.
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(a) To determinewhether the C667T LRP-1 genotypewas associated
with global amyloid load, a regression analysis was performed
using the C/cv[11C]PiB uptake as dependent variable and
the C667T LRP-1T allele frequency as independent variable. A
signiﬁcance threshold of 0.05 was applied to this analysis.
(b) To identify possible modiﬁers of the association between C667T
LRP-1T allele frequency and amyloid load, a regression analysis
was performed using the C/cv[11C]PiB uptake as dependent var-
iable, the LRP-1T allele frequency as independent variable and
stepwise adding of the following independent variables to the
model: age, gender, ApoE genotype, and education. Variables
resulting in an increased adjusted R2 were included in the ﬁnal
model.
(c) To determine possible regional differences of the strength of the
association between C667T LRP-1T allele frequency and amyloid
load, a voxel based regression analysis was performed with the
[11C]PiB images as dependent variable, LRP-1T allele frequency
as independent variable, controlling for all variables identiﬁed
in the before mentioned regression analysis (b) as modiﬁers
using statistical parametric mapping version 8 (SPM8) (Friston
et al., 1994). As a pre-processing method for this analysis, the
individual spatially normalized [11C]PiB images were quantita-
tively normalized to the cerebellar vermis and were smoothed
(Gaussian kernel of 10 × 10 × 10 mm) (Grimmer et al., 2009a,
b, 2010). For the voxel based regression analysis a cluster signif-
icance threshold of 0.05 corrected for multiple comparisons
(family-wise error: FWE) was applied.
(d) To investigate an interaction between ApoE and LRP-1 genotypes,
a correlation analysis between frequency of ApoE ε4 alleles and of
LRP-1T alleles was calculated. Moreover, the interaction term
ApoE ε4 × LRP-1 was included as an additional independent var-
iable in the abovementioned regression analysis (b). Further, two
regression analyses were performed accordingly to the before
mentioned regression analysis (b) after stratifying patients into
ApoE ε4 carrier and non-carrier sub-groups.
(e) Additional analyses — To exclude that the previous associations
are caused by a sample bias, i.e. patients with T alleles that are
in a more advanced stage of the disease, correlation analyses
between frequency of T alleles and clinical severity measured by
the CDR SOB as well as age were performed.
3. Results
3.1. Patients
The characteristics of the patient sample including clinical character-
istics, C667T allele frequency and C/cv[11C]PiB uptake ratios are shown
in Table 1.
3.2. Conducted analysis
(a) The regression analysis using the C/cv[11C]PiB uptake as depen-
dent variable and the LRP-1 T allele frequency as independent
variable was statistically signiﬁcant (p = 0.046). Adjusted R2
was 0.042, and the standardized coefﬁcient β for LRP-1T allele
frequency was 0.236. This indicates that the LRP-1T allele is
moderately but signiﬁcantly associated with a higher global
amyloid load in AD patients.
(b) In the regression analysis using the C/cv[11C]PiB uptake as de-
pendent variable and the LRP-1T allele frequency as independent
variable, the variables ApoE genotype and gender were addition-
ally included. In this model the adjusted R2 was 0.140 with a sta-
tistical signiﬁcance of p = 0.004. The standardized coefﬁcient β
for LRP-1T allele frequencywas 0.215 (p= 0.057). This indicatesthat the model controlled for copies of ApoE ε4 and gender
explains 14.0% of the variability of the progression of [11C]PiB
uptake, and that the frequency of the C667T T allele is positively
correlated with the increase of [11C]PiB uptake.
(c) The voxel-based regression analysis with the C/cv[11C]PiB uptake
as dependent variable and LRP-1T allele frequency as indepen-
dent variable, controlling for copies of ApoE ε4 and gender, is
depicted in Fig. 1. The associations were predominantly
temporo-parietal and in regions nearer to the brain surface. A
scatterplot of the association at the local maximum in the right
middle temporal gyrus is provided in Fig. 2.
(d) The correlation analysis between the number of ApoE ε4 and of
LRP-1T alleles was not statistically signiﬁcant (p = 0.470). In
addition, the coefﬁcient of the variable ApoE ε4 × LRP-1T allele
frequency included in the regression analysis (b) was not signiﬁ-
cant. Both results consistently indicate that there is no substantial
association between ApoE and LRP-1 genotypes in this sample.
However, in the sub-group analyses in the ApoE ε4 carriers and
non-carriers the statistical model was signiﬁcant in the ApoE ε4
carrier sub-group (p= 0.018; adjusted R2= 0.141, standardized
coefﬁcient β for LRP-1T allele frequency= 0.378, p = 0.013) but
not in the ApoE ε4 non-carrier sub-group (p = 0.794).
Scatterplots of these two analyses are shown in Fig. 3.
(e) The correlation analyses of the LRP-1 genotype with CDR SOB or
with age were not signiﬁcant either (p = 0.145 and p = 0.318,
respectively).
4. Discussion
In this study, we found a signiﬁcant positive association between the
numbers of T alleles of LRP-1 C667T polymorphism on chromosome 12
and global amyloid load in a cohort of 72 AD patients. The strength of
the association showed regional variability with associations predomi-
nantly in temporo-parietal areas and in brain regions nearer to the
cortex. In addition, we were able to show that this association is stron-
ger in ApoE ε4 carriers.
In a previous in-vivo study in humans we were able to demonstrate
that amyloid clearance processes are important for the development of
cerebral amyloid deposits. Speciﬁcally, we showed that white matter
lesions indicating impaired perivascular drainage pathways are associ-
ated with increased rates of amyloid deposition in AD patients
(Grimmer et al., 2012). The current study provides further hints that
amyloid clearance pathways are relevant for the development of cere-
bral amyloid load in AD. Thus, it may be interesting to examine pharma-
cological strategies increasing the transporting capacity of LRP-1 in AD
patients. For example Rifampicin alters the brain efﬂux index of Aβ by
inducing LRP-1 (Qosa et al., 2012).
A meta-analysis including 4668 AD patients and 4473 controls was
not able to demonstrate a difference in the rates of T alleles between
healthy controls and AD patients (Pritchard et al., 2005). This ﬁnding
could potentially be explained that the control groups of these studies
Fig. 1. Voxel-based regression analysis between the C/cv[11C]PiB uptake ratio and the frequency of LRP-1T alleles, controlled for copies of the ApoE ε4 allele and sex. Signiﬁcant (p b 0.05,
corrected formultiple comparisonsusing familywise error) correlations are depicted in yellow andare projected on axial T1-MRI scans (average of 152 scans, implemented in SPM8), num-
bers indicate z-coordinates of slices in Talairach space in mm. LRP-1 T allele: Low Density Lipoprotein receptor-related protein C667T polymorphism; [11C]PiB: Pittsburgh compound B.
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symptomatic AD. However, more likely the LRP-1 polymorphism does
not protect against the disease but modiﬁes its course.
The ApoE ε4 gene dose itself which was included as a control
variable explained variability of [11C]PiB uptake (p = 0.003) which
is consistent with other association studies (Drzezga et al., 2009;Fig. 2. Scatter plot of the voxel-based analysis with mean [11C]PiB uptake as dependent
variable and LRP-1 T allele frequency as independent variable, controlling for copies of
ApoE ε4 and gender at the local maximum of x = 48, y =−12, z =−14 (coordinates
in Talairach space in mm). LRP-1 T allele: Low Density Lipoprotein receptor-related pro-
tein C667T polymorphism; [11C]PiB: Pittsburgh compound B.Grimmer et al., 2010). ApoE and LRP-1 are both involved in clearance
pathways for β-amyloid (Castellano et al., 2011). The ApoE ε4 allele
as well as the LRP-1T allele are potential risk factors for AD (Bahia
et al., 2008).
What is interesting is that in sub-group analyses the association be-
tween LRP-1 and amyloid load was only signiﬁcant in ApoE ε4 carriers
while the interaction term LRP-1 × ApoE ε4 in the regression analysis
of the whole sample was not signiﬁcant. Differences between ApoE ε4
carriers and non-carriers with regard to LRP-1 transport would be con-
sistent with pre-clinical ﬁndings (Castellano et al., 2011). Amyloid can
be transported by LRP-1 as an ApoE–Aβ complex. The uptake of
ApoE–Aβ complexes by astrocytes is mediated by LRP-1. These com-
plexes undergo transcytosis and subsequent perivascular drainage.
ApoE ε2 andApoE ε3 aswell as Aβ–ApoE ε2 and Aβ–ApoE ε3 complexes
are cleared at the BBB via LRP-1 at a substantially faster rate than the
Aβ–ApoE ε4 complex. (Deane et al., 2008). However, a lack of statistical
power would be another possible explanation for the non-signiﬁcant
result in the ApoE ε4 non-carrier sub-group.4.1. Regional variability
The voxel-based analysis of the association between LRP-1 and brain
amyloid load revealed that the association occurs predominantly in
temporo-parietal brain areas and appears to be somewhat stronger in
cerebral regions close to the cortical surface. This observation is consis-
tent with the assumption that deeper brain regions have other ways of
drainage i.e. diffusion directly into the CSF (Szentistvanyi et al., 1984). It
would also be in line with the ﬁnding that the association between
amyloid measured in the CSF and cerebral amyloid is strongest in
brain regions adjacent to the CSF (Grimmer et al., 2009b).
Fig. 3. Scatterplots of sub-group regression analysis after stratifying patients into
ApoE ε4 carriers and non-carriers using the C/cv[11C]PiB uptake as dependent vari-
able, the LRP-1 T allele frequency as independent variable controlling for gender.
A) in ApoE ε4 carriers: signiﬁcant model (p= 0.018); adjusted R²= 0.141, standard-
ized coefﬁcient ß for LRP-T allele frequency = 0.378 (p = 0.013). B) in ApoE ε4 non-
carriers: not signiﬁcant (p = 0.794). ApoE: apolipoprotein E; LRP-1 T allele: Low
Density Lipoprotein receptor-related protein C667T polymorphism; [11C]PiB: Pitts-
burgh compound B.
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One limitation is the small sample size. p values of the associations
between C667T LRP-1T allele frequency and global amyloid load were
near the threshold for statistical signiﬁcance. After the post-hoc analysis
excluding the homozygote for LRP-1T allele, β coefﬁcients for LRP-1T
allele frequency are no longer signiﬁcant in analyses (a) and (b) but in
the sub-group analysis in ApoE ε4 carriers (p = 0.110, p = 0.093, and
p = 0.048, respectively). Therefore, it would be important to replicate
our ﬁnding in larger cohorts. AD was diagnosed using the standard
criteria for probable AD (McKhann et al., 1984), but the clinical diagnosis
of ADwas not conﬁrmed by post-mortem examination to avoidmisclas-
siﬁcation of patients as AD. However, patients were only enrolled if they
showed AD-typical ﬁndings on [18F]FDG-PET. Thus, they also fulﬁlled the
new NIA-AA criteria of probable AD dementia with evidence of the AD
pathophysiological process (McKhann et al., 2011). On the other hand,
this additional inclusion criterion might have biased patient selection.5. Conclusions
In conclusion, an LRP-1 polymorphism is signiﬁcantly associated
with amyloid deposition. This is compatiblewith the view that impaireddrainage systems are causative for amyloid deposition and possibly for
the development of AD.
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